# Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

Study · id `cardio:ct-nct06220032` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06220032](<https://clinicaltrials.gov/study/NCT06220032>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06220032

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 324 participants.

## Technical summary

Registry record NCT06220032. Randomized; no masking; primary purpose treatment. Start 2024-08-15 (actual); primary completion 2028-12-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 324 participants (planned count; ClinicalTrials.gov record NCT06220032, source copy `cardio:ctgov-nct06220032-2026-09-23`, retrieved 2026-10-26)
- Started: 2024-08-15 (actual) (ClinicalTrials.gov record NCT06220032, source copy `cardio:ctgov-nct06220032-2026-09-23`, retrieved 2026-10-26)
- Primary completion: 2028-12-15 (anticipated) (ClinicalTrials.gov record NCT06220032, source copy `cardio:ctgov-nct06220032-2026-09-23`, retrieved 2026-10-26)
- Completion: 2028-12-15 (anticipated) (ClinicalTrials.gov record NCT06220032, source copy `cardio:ctgov-nct06220032-2026-09-23`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT06220032, source copy `cardio:ctgov-nct06220032-2026-09-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06220032-2026-09-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
- Acronym: HO170DLBCL
- Condition: DLBCL - Diffuse Large B Cell Lymphoma
- Intervention (Drug): Dexrazoxane
- Intervention (Drug): Rituximab
- Intervention (Drug): Cyclophosphamide
- Intervention (Drug): Doxorubicin
- Intervention (Drug): Vincristine
- Intervention (Drug): Prednisolone
- Intervention (Drug): Lenalidomide
- Intervention (Drug): Pegfilgrastim
- Lead sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
- Lead sponsor class: OTHER
- Collaborator: UMC Utrecht
- Collaborator class: OTHER
- Collaborator: Amsterdam UMC, location VUmc
- Collaborator class: OTHER
- Collaborator: The Dutch Network for Cardiovascular Research (WCN)
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as a collaborator: UMC Utrecht (`cardio:org-umc-utrecht`)
- Registry lists this organization as a collaborator: Amsterdam UMC, location VUmc (`cardio:org-amsterdam-umc-location-vumc`)

## Provenance

Content hash: 029f10f421a2e98ddf6f71f0d7000a4c00cb60210971cf273527ffcb0ab615e5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
